Outsourcing Pharma

AUGUST 8, 2022

The pharmaceutical company has forged a partnership with the nanotechnology specialist to use nanoparticle tech and formulation to advance its products.

Bioavailability 52

Bioavailability Branding Medicine Production 52

XTalks

JANUARY 30, 2025

This additional six months of market exclusivity can translate into significant revenue , offering pharmaceutical companies a lucrative opportunity to capitalize on branded drug sales during this extended period. Advanced formulation techniques are often required to improve the solubility and bioavailability of these APIs.

Manufacturing 52

Manufacturing Development Compliance Production 52

XTalks

FEBRUARY 25, 2022

After five years of research and development, the brand found a way to transform saved grain from brewing into nutrient-rich, barley-based proteins and fibers that have a variety of applications in the food and beverage industry. EverGrain’s UFA Certification. Related: Will Pecan Milk Find Success in the Crowded Plant-Based Dairy Space?

Production 98

Production Protein Branding Bioavailability 98

Pharmaceutical Technology

AUGUST 22, 2022

They also offer enhanced bioavailability, exact dosing and an extended shelf life. For companies, it creates possibilities for portfolio diversification and brand differentiation. Softgel capsules, containing a liquid, paste or emulsion active ingredient, are trusted and favoured by many patients. Chewable capsules and gummies.

Compliance 130

Compliance Bioavailability Containment Branding 130

XTalks

JUNE 14, 2023

Furthermore, the bioavailability of the active pharmaceutical ingredient (API) into the cornea is up to four times stronger with EyeSol technology. This innovative approach signifies a significant milestone in addressing the limitations of conventional eye care therapies. for a 30-day supply (without insurance coverage).

Gene Silencing 97

Gene Silencing Drug Delivery FDA Approval RNA 97

pharmaphorum

NOVEMBER 9, 2022

He continued: “We are impressed by the potential of NRG’s small molecules as orally-bioavailable and brain-penetrant treatments and look forward to working with the team to move the programmes through IND-enabling studies.”. It has been supporting NRG’s work since 2019.

In-Vitro 52

In-Vitro Bioavailability Medicine Clinical Trials 52

Delveinsight

AUGUST 10, 2020

Nintedanib is an orally bioavailable, small-molecule tyrosine kinase inhibitor (TKI) developed for the treatment of IPF and SSc-ILD. Boehringer Ingelheim is worth mentioning here, as it is presenting key posters and studies on Ofev’s SENSCIS Trial and INBUILD Trial. Ofev (Nintedanib) Facts. Ofev (Nintedanib) Approval History.

Drugs 52

Drugs Trials Bioavailability FDA Approval 52